Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018
Data presented today from TRANSCEND CLL-004 include 16 patients from the ongoing phase 1 monotherapy dose-escalation part of the study. The median number of lines of prior therapy was 4.5, and 75......
最新文章
【不專業地下電台EP3】原來雞精是這個成分在給元氣！不愛雞精味竟然有這樣的取代方式？雞湯、雞精、滴雞精、熬雞精跟素雞精有什麼差別？ | 健談havemary.com - 圖解健康生活大小事
排便不順使糞便囤積、腸道壞菌增多 皮膚跟著惡性循環怎麼解？ | 健談havemary.com - 圖解健康生活大小事
【不專業地下電台EP4】過年送禮該怎麼送才健康？長輩收禮究竟會注意什麼？ | 健談havemary.com - 圖解健康生活大小事
【不專業地下電台EP5】魚油、魚肝油你懂吃嗎？ | 健談havemary.com - 圖解健康生活大小事
【不專業地下電台EP6】兒童過敏知多少？ | 健談havemary.com - 圖解健康生活大小事
